Published online Mar 24, 2024. doi: 10.5306/wjco.v15.i3.378
Peer-review started: December 16, 2023
First decision: January 10, 2024
Revised: January 23, 2024
Accepted: February 23, 2024
Article in press: February 23, 2024
Published online: March 24, 2024
Processing time: 96 Days and 15 Hours
Cancer immunotherapy is an effective with critical approaches in the treatment of oncological patients. Whilst numerous research and clinical trials are underway to develop endogenous immunotherapy approaches, it is necessary to focus on fundamental issues and identify barriers to basic clinical progress. Addressing these challenges and the new pathways will require researchers and clinicians to join forces to accelerate the understanding of the complex interactions between cancer and the immune system and focus resources on developing better treatments for patients.
Core Tip: Immunotherapy has emerged as a potent treatment for specific cancer types, which evokes enduring reactions and sometimes even induces remission. Nevertheless, the efficiency of this method relies both on the type of malignancy involved and individual patient traits. Additionally, it is administered in tandem with surgical interventions or chemotherapy/radiation regimens. It holds promise but could not act as a panacea; ongoing studies focus on enhancing its efficacy levels while comprehending underlying mechanisms more precisely.